CASI Pharmaceuticals Inc. (CASI)
NASDAQ: CASI
· Real-Time Price · USD
1.89
-0.02 (-1.05%)
At close: May 15, 2025, 2:23 PM
-1.05% (1D)
| Bid | 1.86 |
| Market Cap | 29.2M |
| Revenue (ttm) | 28.54M |
| Net Income (ttm) | -39.26M |
| EPS (ttm) | -2.56 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -1.06 |
| Analyst | Buy |
| Ask | 1.9 |
| Volume | 8,685 |
| Avg. Volume (20D) | 9,336 |
| Open | 1.97 |
| Previous Close | 1.91 |
| Day's Range | 1.87 - 1.97 |
| 52-Week Range | 1.64 - 7.67 |
| Beta | 0.76 |
About CASI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CASI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CASI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
CASI Pharmaceuticals Inc. is scheduled to release its earnings on May 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+0.95%
CASI Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
10 months ago
+36.49%
CASI Pharmaceuticals shares are trading higher after the company announced plans to submit an Investigational New Drug application to the FDA for CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients. Also, the company received a preliminary non-binding proposal letter from CEO and Chairman Wei-Wu He to acquire its business operations in China.
